conjugated nanobodies against epidermal growth factor receptor (EGFR; a marker of tumor cells) and intercalated water‐soluble platinum‐based drug molecules to a double‐bundle DNA tetrahedron (Figure 7e).[172] Similarly, the authors proved the i.v. delivery of the tetrahedra to the A431 tumor xenograft model (Figure 7f) and detected tumor inhibition. The gene discussed is EGFR; the disease is neoplasm.